Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimustine + dacarbazine + vincristine
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents—nimustine, dacarbazine, and vincristine. Each drug has a distinct mechanism of action targeting cancer cells: - **Nimustine** is an alkylating agent from the nitrosourea class that crosslinks DNA strands, inhibiting DNA replication and transcription. - **Dacarbazine** is also an alkylating agent (triazene derivative) that works by methylating guanine bases in DNA, leading to inhibition of DNA synthesis and function. - **Vincristine** is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation required for mitosis. This combination has been used in the treatment of various malignancies. There are published reports describing its use in regimens for high-grade glioma and other cancers. The combination exploits different mechanisms to maximize antitumor activity[2][5].
- Other names
- nimustine hydrochloride + dacarbazine + vincristine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on nimustine + dacarbazine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimustine + dacarbazine + vincristine.